TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: AUC of ethinyl estradiol and levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruitment rate for participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant satisfaction assessed by a likert scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completion of study outcome measures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to intervention by participants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area under the serum insulin curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Self-Stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Uniformity of Aerosol Distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in FVIII Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With a Solicited Injection-site Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With a Solicited Systemic Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With a Vaccine-related Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of ER Positive Breast Cancer and Metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anti-HBs antibodies concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum levels of TNF-a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: UI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in OCD Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 5-year Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Serum Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Graft Size Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma analyte concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Last observed measurable analyte concentration (Clast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RNA expression of urine biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in EuroQoL-5 Dimension (EQ-5D) index score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensitivity and specificity of uPAR PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Glasgow Prognostic Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion of Atrial Fibrillation to Sinus Rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: door-to-CT time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in mRNA Expression in Blood of STAT3, PPAR-ɣ, and STC-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improved Sexual Function
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Improved Vaginal Laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measuring Sexually Related Personal Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 30 days mortality after injury or illness
Endpoint domain: Mortality/survival
Primary endpoint: Neurologic outcome at 6 months after injury or illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Cardiorespiratory Fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: recurrence rate of emergence agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAS-cog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: systolic arterial pressure fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in TB-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Synovial concentration of IL-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Grade of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Doses (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pulmonary artery pressures (PAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Analysis of E. coli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Detection Accuracy (PDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Witnessed Doses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of events of respiratory depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 28 day survival
Endpoint domain: Mortality/survival
Primary endpoint: Disease control rate (DCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Objective and relative (%) reduction of the involved skin surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline in sitting blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Adverse Events of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of pancreatitis post ERCP
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of pancreatitis post ESWL
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Disease-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Presence of Molar incisor hypomineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Duration of Day Time Wear Time of the Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Satisfaction Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HBV serologic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alanine transaminase (ALT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Brief Test of Adult Cognition by Telephone (BTACT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum concentration (Cmax) of omaveloxolone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the omaveloxolone concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of total radioactivity in blood and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of operant responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients with pain relief at 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver Enzymes (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Worse Eye Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children Organizational Skills Scale (COSS)-parent
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: IVD performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vancomycin target trough achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrous cap thickness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical and Global Performance of the Surgical Trainee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Composite Endpoint of Cardiac Death and Myocardial Infarction
Endpoint domain: Mortality/survival
Primary endpoint: Patient well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of fasciculations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fibroglandular Tissue in Total Breast (FGBT%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast Density by Mammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient level data accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Vascular Resistance Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Pediatric Agitation/Emergence Delirium Scale (PAED) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Aging Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Restoration effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle joints power generation in stance phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Internet use (hours/day)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Urinary microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ishak fibrosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Body Mass Index z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving IGA 0 or 1 from Monotherapy Studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving IGA 0 or 1 from Combination Therapy Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathologic Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of Volatile Organic Compound (VOC) profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjudication of silent stroke
Endpoint domain: Mortality/survival
Primary endpoint: Adjudication of new strokes
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from ventricular fibrillation or ventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of occlusal caries lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Daily Opioid Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive Disease Free Survival (iDFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in frequency of verbal mistreatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the number of positive aspects of the relationship with the care recipient
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aberrant Behavior Checklist (ABC) irritability score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transplant free survival
Endpoint domain: Mortality/survival
Primary endpoint: Tolerability as measured by number of subjects with dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Safety as measured by number of subjects with Adverse Events using CTCAE
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability as measured by adverse events using CTCAE and clinical laboratory parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Change in global left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wait time for treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical response (non-failure) to assigned treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth in Abdominal Aortic Aneurysm MTD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Overall satisfaction rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in WIQ Distance Subscore
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in WIQ Speed Subscore
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in WIQ Stair-Climbing Subscore
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in SF-36 PCS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in SF-36 MCS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anatomic dead space change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficiency of CO2 removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for endotracheal ventilation or switch to another mode of NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Weekly Average of Daily Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital readmissions because of HF
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Acceptance rate of clinical pharmacist's recommended interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Implementation rate of clinical pharmacist's recommended interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Impact of the clinical pharmacist on the identification and management of TRPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of anti VEGF injections
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Visual Acuity (Letters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cephalic presentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Zinc Absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in metamemory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement of suboptimal health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to negative PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Subjects Achieving Clear or Almost Clear PGA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief during omissions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Labor progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative S-ICD Complication Free Rate up to 7 days post implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of inappropriate shocks for AF/SVT
Endpoint domain: Adverse events/effects
Primary endpoint: Duration and severity of illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Solicited & unsolicited adverse events and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Superoxide dismutase (SOD) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Catalase (CAT) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of dysautonomic sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant perceived utility of ultrasound guided nerve block
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Observed Concentration in Plasma (Cmax) of Pexidartinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUClast and AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level following surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipids (HDL, LDL, total cholesterol, triglycerides)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of severe CRS
Endpoint domain: Adverse events/effects
Primary endpoint: Change of RAS mutant clones in the metastatic lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: High grade dysplasia (AIN 2/3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: successful colon cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Axial Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gain of each canal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rise of NGAL in AKI after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: efficacy of the regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Muscle Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma tenofovir concentration-time curve (AUC0-72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical tissue tenofovir maximum concentration (Cmax) at 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All adverse clinical and laboratory events
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pre-bronchdilator FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in adiponectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Low Back Pain Perception (LBPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Radial Displacement (Dm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Dose-limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Discrimination of VOC bio-markers between Breast Cancer and healthy population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Remission or Clinical Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Abstinent rate at 25 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of concussive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes